Medical Information

The contraindications for Pacritinib mainly include patients with severe heart block and active bleeding, and strict adherence to contraindication standards is necessary to ensure medication safety. The following provides a detailed explanation of precautions from three aspects: specific contraindications, risk assessment, and alternative solutions.

1. Severe heart block patient

(1) Absolute contraindication: Patients with baseline QTc interval>500ms or with grade II or higher atrioventricular block are prohibited from using the medication as it may increase the risk of arrhythmia.

(2) Risk assessment: Prior to medication, a complete electrocardiogram examination is required. For patients with electrolyte imbalances, hypokalemia/hypomagnesemia should be corrected before evaluation.

2 active bleeding patients

(1) Taboo scope: including gastrointestinal bleeding, intracranial bleeding, and recent major surgery (<4 weeks) patients, as drugs may inhibit platelet function.

(2) Risk management: Avoid using anticoagulant/antiplatelet drugs during treatment, and suspend medication for mild bleeding symptoms such as hemorrhoid bleeding.

3 Other high-risk taboo groups

(1) Severe liver damage: Not recommended for Child Pugh C patients as drug metabolism disorders may lead to toxic accumulation.

(2) Pregnancy period: Animal studies have shown embryotoxicity, and pregnant women and women planning to conceive should avoid it throughout the entire process.

4 alternative treatment options

(1) High risk heart patients: JAK inhibitors such as rosotinib with lower risk of QT prolongation may be considered, but platelet count needs to be evaluated.

(2) Patients with bleeding tendency: It is recommended to use non pharmacological therapies such as thrombopoietin receptor agonists or transfusion support for transition.